TD Cowen Downgrades Oak Street Health to Market Perform, Raises Price Target to $39
TD Cowen analyst Gary Taylor downgrades Oak Street Health (NYSE:OSH) from Outperform to Market Perform and raises the price target from $34 to $39.
SVB Leerink Downgrades Decibel Therapeutics to Market Perform, Lowers Price Target to $2
SVB Leerink analyst Mani Foroohar downgrades Decibel Therapeutics (NASDAQ:DBTX) from Outperform to Market Perform and lowers the price target from $7 to $2.
Compass Point Downgrades Acushnet Hldgs to Neutral, Lowers Price Target to $55
Compass Point analyst Casey Alexander downgrades Acushnet Hldgs (NYSE:GOLF) from Buy to Neutral and lowers the price target from $65 to $55.
Sidoti & Co. Upgrades Universal Electronics to Buy, Announces $16 Price Target
Sidoti & Co. analyst Gregory Burns upgrades Universal Electronics (NASDAQ:UEIC) from Neutral to Buy and announces $16 price target.
Guggenheim Maintains Buy on Smartsheet, Raises Price Target to $54
Guggenheim analyst John Difucci maintains Smartsheet (NYSE:SMAR) with a Buy and raises the price target from $48 to $54.
Guggenheim Maintains Buy on RAPT Therapeutics, Lowers Price Target to $48
Guggenheim analyst Yatin Suneja maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and lowers the price target from $55 to $48.
B of A Securities Upgrades Discover Finl to Neutral, Announces $107 Price Target
B of A Securities analyst Mihir Bhatia upgrades Discover Finl (NYSE:DFS) from Underperform to Neutral and announces $107 price target.
Barrington Research Reiterates Outperform on American Public Education, Lowers Price Target to $10
Barrington Research analyst Alexander Paris reiterates American Public Education (NASDAQ:APEI) with a Outperform and lowers the price target from $15 to $10.
Expert Ratings for ShockWave Medical
ShockWave Medical (NASDAQ:SWAV) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $12 Price Target
Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $12 price target.